71.62
前日終値:
$71.60
開ける:
$71.66
24時間の取引高:
3.80M
Relative Volume:
0.82
時価総額:
$11.16B
収益:
$1.21B
当期純損益:
$109.52M
株価収益率:
102.87
EPS:
0.6962
ネットキャッシュフロー:
$269.60M
1週間 パフォーマンス:
-0.03%
1か月 パフォーマンス:
+0.87%
6か月 パフォーマンス:
+4.97%
1年 パフォーマンス:
+21.84%
Bio Techne Corp Stock (TECH) Company Profile
Compare TECH vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TECH
Bio Techne Corp
|
71.62 | 11.16B | 1.21B | 109.52M | 269.60M | 0.6962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | アップグレード | Citigroup | Neutral → Buy |
| 2025-07-22 | 再開されました | Stephens | Overweight |
| 2025-07-09 | 開始されました | TD Cowen | Buy |
| 2025-05-30 | 開始されました | Wells Fargo | Overweight |
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 開始されました | Evercore ISI | Outperform |
| 2025-02-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-08 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-02 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-08-28 | 開始されました | William Blair | Outperform |
| 2023-01-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-04-25 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | アップグレード | Stifel | Hold → Buy |
| 2021-01-25 | 繰り返されました | The Benchmark Company | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-07-15 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | ダウングレード | Stifel | Buy → Hold |
| 2020-05-14 | 開始されました | The Benchmark Company | Buy |
| 2020-01-08 | 再開されました | Stephens | Overweight |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Neutral |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-07-02 | アップグレード | Janney | Neutral → Buy |
| 2019-01-14 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | ダウングレード | Craig Hallum | Buy → Hold |
| 2018-10-17 | 開始されました | Goldman | Neutral |
| 2018-06-15 | 開始されました | Argus | Buy |
| 2017-07-13 | 開始されました | Wells Fargo | Market Perform |
| 2017-02-09 | 開始されました | Citigroup | Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Buy |
| 2016-11-10 | 再開されました | Leerink Partners | Outperform |
| 2015-01-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2013-09-20 | アップグレード | Robert W. Baird | Neutral → Outperform |
すべてを表示
Bio Techne Corp (TECH) 最新ニュース
Bio-Techne Corp (TECH) SVP option exercise and share withholding - Stock Titan
Bio-Techne Corp (TECH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio-Techne Corp (TECH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TECH|Bio-Techne Corp|Price:71.600|Chg%:-0.170 - TradingKey
Bio-Techne Corp (TECH) Institutional Confidence - TradingKey
Bio-Techne Corp Revenue Breakdown – NASDAQ:TECH - TradingView
Bio-Techne Corp (TECH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
What to Expect From Bio-Techne's Next Quarterly Earnings Report - Barchart.com
(TECH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Bio-Techne Corp (TECH) Hovers Near Support Amid Modest DeclinePCR Spike - dars.gov.et
Bio-Techne Corp (TECH) Stock Analysis: Navigating the Biotechnology Landscape Amidst Revenue Challenges - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Holds Steady Near Support as Slight Gains Signal StabilizationAI Trade Signals - dars.gov.et
RBC Capital downgrades Bio-Techne stock rating on acquisition view By Investing.com - Investing.com Nigeria
RBC Capital downgrades Bio-Techne stock rating on acquisition view - Investing.com
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio - Investing News Network
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Slips SlightlyHealthcare Earnings Report - DonanımHaber
Bio-Techne expands AI-engineered protein portfolio for cell therapy - Investing.com
Bio-Techne expands AI-engineered protein portfolio for cell therapy By Investing.com - Investing.com UK
Bio-Techne expands designer proteins for cell therapy and organoids - Stock Titan
Bio-Techne Corp : RBC Cuts to Sector Perform - Moomoo
Form DEF 14A Bio-Techne Corp For: 7 July By Investing.com - Investing.com Canada
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Eases LowerCost Structure Review - dars.gov.et
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates Amidst Cautious Demand EnvironmentDividend Cut Risk - dars.gov.et
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA) - The Globe and Mail
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Donald TrumpBIO TECHNE CORP COM UNSOLICITED Trump Trade on Mar. 23, 2026 - Quiver Quantitative
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
Merck KGaA inks $11.3bn buy of Bio-Techne in largest deal in a decade - BioXconomy
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Bio-Techne Corp (TECH) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges HigherEarnings Momentum Score - dars.gov.et
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio Techne Corp (TECH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):